Redesca HP

**Redesca HP** is a brand name for a high-potency formulation of enoxaparin sodium, a low molecular weight heparin (LMWH) anticoagulant available as preservative-free prefilled syringes (e.g., 120 mg/0.8 mL, 150 mg/1 mL) with anti-Factor Xa activity of approximately 100 IU/mg and solution pH 5.5-7.5. It binds to and potentiates antithrombin III to form a complex that irreversibly inactivates clotting factor Xa (with less effect on factor IIa/thrombin compared to unfractionated heparin), preventing thrombus formation. Developed by Shenzhen Techdow Pharmaceutical Co., Ltd. and marketed in Canada since December 2020 (marketed status as of 2021), it is indicated for prophylaxis and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), acute ST-segment elevation myocardial infarction (STEMI) in combination with aspirin, unstable angina/non-Q-wave MI, and clot prevention during hemodialysis or in high-risk surgical/medical patients.[1][2][3][5][7][8][10]

Brand names

Redesca HP

Other names

Redesca